Dupilumab in the Treatment of Cutaneous Lymphoid Hyperplasia

Key Points

• The study aims to evaluate the effectiveness of dupilumab in treating cutaneous lymphoid hyperplasia.
• Clinical observations and assessments were conducted to evaluate treatment outcomes.
• Treatment involved administering dupilumab to affected individuals.
• Patient responses to therapy were monitored over time.
• Dupilumab treatment showed improvement in skin lesions associated with cutaneous lymphoid hyperplasia.
• Patients reported reduced symptoms after receiving dupilumab therapy.